Parataxis has invested 25 billion KRW to take control of Bridge Biotherapeutics, planning to rename it Parataxis Korea. The focus will shift towards integrating Bitcoin treasury strategies while retaining existing biotech operations.
Andrew Kim has been appointed as CEO of Parataxis Korea, with Edward Chin joining the board. The management shift aims to leverage expertise in both digital assets and biopharmaceuticals.
The company is set to launch South Korea’s first BTC-native institutional platform, with strategic plans for BTC treasury growth and institutional-grade financial strategies.
Leave a Reply